Opna Bio

We are pleased to announce that the first patient has been treated with OPN-6602, an EP300/CBP bromodomain inhibitor, in our Phase 1 clinical study in relapsed or refractory multiple myeloma. Approximately 180,000 people are diagnosed annually with multiple myeloma, a blood cancer derived from malignant plasma cells in the bone marrow. Additionally, we have expanded our board of directors, naming Axel Bolte, MBA, MSc, to board director and Stephanie Oestreich, PhD, MPA, to board observer. https://lnkd.in/gdFS89Zg

Opna Bio’s Dr. Pan-Yu Chen presents preclinical data at the American Society for Cancer Research (AACR) Annual Meeting on OPN-9840, an oral TEAD inhibitor that demonstrated dose-dependent and on-target in vitro and in vivo efficacy in preclinical models of malignant mesothelioma. Malignant mesothelioma is a rare and aggressive cancer that primarily affects the lining of the lungs or abdomen. For more information on Opna’s presentations at AACR, please visit: https://lnkd.in/gJajNCvY

Opna’s Bernice Matusow, MS, presented research yesterday at AACR on OPN-6602, our EP300/CBP bromodomain inhibitor, which demonstrated potent anti-tumor activity in preclinical models of multiple myeloma. OPN-6602 significantly reduced tumor growth as a single agent (71% tumor growth inhibition) in the OPM-2 human multiple myeloma cell xenograft model as well as increased anti-tumor activity (>100% TGI) in combination studies. Opna plans to initiate a Phase 1 clinical study with OPN-6602 in multiple myeloma patients later this summer. #AACR #multiplemyeloma#Phase1

Our team is looking forward to presenting two abstracts next month at the American Association for Cancer Research (AACR) annual meeting, April 5-10, in San Diego. We will highlight preclinical research with OPN-6602, a dual EP300/CBP bromodomain inhibitor slated to begin a Phase 1 clinical trial in multiple myeloma later this year, and OPN-9840, a potent pan-TEAD inhibitor showing single-agent efficacy in malignant mesothelioma models. #AACR #oncology #multiplemyeloma #malignantmesothelia Abstract Title:: "OPN-6602, A Potent Dual EP300/CBP Bromodomain Inhibitor, Targets Multiple Myeloma Through Concomitant Suppression of IRF4 and c-MYC" Abstract #660 Session Category: Experimental and Molecular Therapeutics Session Title: Novel Antitumor Agents 2 Session Date and Time: Sunday, April 7, 2024 1:30 PM - 5:00 PM PT Location: Poster Section 27 Poster Board Number: 6 Abstract Title: "OPN-9840, A Non-covalent Potent Pan-TEAD Inhibitor, Exhibits Single Agent Efficacy in Preclinical Malignant Mesothelioma Models
Abstract" Abstract #: 7264
 Session Category: Experimental and Molecular Therapeutics
 Session Title: YAP/TAZ/TEAD Modulators
 Session Date and Time: Wednesday Apr 10, 2024 9:00 AM - 12:30 PM PT
Location: Poster Section 28
 Poster Board Number: 1

Opna joins the international myeloma community to help spread awareness of this blood cancer during Multiple Myeloma Awareness month. Multiple Myeloma (MM) develops in plasma cells in the bone marrow, the soft, spongy tissue at the center of your bones. Over time, myeloma cells collect in the bone marrow, forming tumors in many of the body’s bones. These tumors may keep the bone marrow from making enough healthy blood cells and weaken the bones. MM is more common in older people, especially men, and African Americans. Some common symptoms include bone pain, weakness or fatigue, weight loss, frequent infections, and frequent urination. Opna’s OPN-6602, a selective EP300/CBP bromodomain inhibitor, has shown differentiated potency and efficacy in multiple myeloma models. The company expects to begin a first-in-human Phase 1 trial in the U.S. with OPN-6602 in multiple myeloma patients later this year. #multiplemyeloma #Phase1

Sending warm wishes for a joyful holiday season to all!

Opna’s Bernice Matusow presented encouraging preclinical data on OPN-6602 and OPN-6742, our orally bioavailable, highly potent and selective EP300/CBP bromodomain inhibitors. In preclinical human metastatic castration-resistant prostate cancer (mCRPC) models, OPN-6602 suppressed tumor growth and showed a marked, dose-dependent pharmacodynamic response indicative of EP300/CBP inhibition. A first-in-human study of OPN-6602 in cancer patients is planned to begin in 2024. #AACR-NCI-EORTC #mCRPC #EP300. To access poster, go to publications section on the OpnaBio website.

Headed to Boston this weekend for AACR-NCI-EORTC? Make sure to stop by Opna's poster detailing preclinical data with the company's EP300/CBP bromodomain inhibitors in metastatic castration-resistant prostate cancer (mCRPC).

Are you attending the AACR-NCI-EORTC International Conference in Boston next week? We’re looking forward to presenting preclinical data on Opna’s EP300/CBP bromodomain inhibitors, OPN-6602 and OPN-6742, in metastatic castration-resistant prostate cancer (mCRPC).  Details: Sat, Oct 14th, Hynes Convention Center, Abstract #CO85, Poster Session C, Level 2, Exhibit Hall D, 12:30-4 pm ET #AACR-NCI-EORTC #prostatecancer #BETinhibition